xNOS
Biotechnology Research • 
Copenhagen, Capital Region of Denmark, Denmark • 1-10 Employees
Company overview
| Headquarters | Copenhagen, Capital Region of Denmark, Denmark |
| Website | |
| SIC | 581 |
| Founded | 2016 |
| Employees | 1-10 |
Key Contact at xNOS
Marina Zaferan
Co-Founder
About xNOS
xNOS is a biotechnology company that specializes in developing a multi-target therapeutic compound for treatment of sexual dysfunction in both women and men with type 1 and type 2 diabetes mellitus. The company was founded in 2016 and today has developed a novel target drug candidate Xoin® (xNOSniox). xNOS's comprehensive molecular expertise is expected to lead to a stream of future innovative commercial products. Nitric oxide technology is a key focus of xNOS's strategy. xNOS's technology base consists of validated and proprietary next-generation endothelial nitric oxide synthase (eNOS) activator therapies.
xNOS revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
xNOS has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
xNOS has never raised funding before.
xNOS Tech Stack
Discover the technologies and tools that power xNOS's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Security
Ecommerce
Security
Miscellaneous
JavaScript libraries
JavaScript libraries
CMS
Font scripts
United States
Australia
France
United KingdomFrequently asked questions
4.8
40,000 users
